other material
confidence high
sentiment positive
materiality 0.70
Enanta reports positive Phase 2 data for zelicapavir in pediatric RSV: 1.4 log viral load drop at Day 5
ENANTA PHARMACEUTICALS INC
- Part 2 primary endpoint: 1.4 log viral load decline at Day 5 vs placebo (n=34 zelicapavir, n=10 placebo).
- Prespecified early-treatment subset (within 3 days of symptom onset): 1.2 log decline at Day 5 vs placebo.
- 96 patients (70 zelicapavir, 26 placebo) aged 28 days to 36 months; no AEs leading to discontinuation.
- Dose selected: 5 mg/kg for ≥28 days to <12 months; 7.5 mg/kg for ≥12 to ≤36 months.
- Symptom tool RESOLVE-P showed trend toward reduction but data available for only 15 patients.